MEDICUS PHARMA LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.79 CAD | -10.05% |
|
-10.05% | -10.50% |
| 05-29 | Medicus Pharma Files Registration Statement for Proposed Initial Public Offering in the United States | MT |
| 04-25 | Medicus Pharma Ltd. announced a financing transaction | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2023 * | - | Sales 2024 * | - | Capitalization | 28.91M 20.99M 1.65B |
|---|---|---|---|---|---|
| Net income 2023 * | - | Net income 2024 * | - | EV / Sales 2023 * | - |
| Net cash position 2023 * | - 0 0 | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | - |
| P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-
| Employees | - |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 52.65% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -10.05% | ||
| 1 week | -10.05% | ||
| Current month | -10.05% | ||
| 1 month | -16.74% | ||
| 3 months | -25.42% | ||
| 6 months | -16.74% | ||
| Current year | -10.50% |
1 week
1.79
1.95
1 month
1.792.20
Current year
1.793.00
1 year
0.313.05
3 years
0.313.05
5 years
0.313.05
10 years
0.313.05
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/06/24 | 1.79 | -10.05% | 3,100 |
| 31/05/24 | 1.99 | -0.50% | 300 |
Delayed Quote Toronto S.E., June 07, 2024 at 08:59 pm
More quotes
Medicus Pharma Ltd. is a clinical stage, multi-strategy holding company focused on investing in novel life sciences and bio-technology companies through Food and Drug Administration (FDA) approved clinical trials. The Company identifies, acquires and advances relatively de-risked clinical stage assets through clinical development and commercialization. The Company is exploring to expand its drug development pipeline through acquisitions and partnerships. The Company, through its subsidiary, SkinJect, Inc., is focused on the development of a drug delivery system using novel dissolvable microneedle arrays for the treatment of certain skin cancers. SkinJect is a novel, minimally invasive treatment for common forms of non-melanoma skin cancer, basal cell and squamous cell carcinoma.
Sector
Pharmaceuticals
Calendar
25/06/2024
- Annual General Meeting
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.50% | 21.02M | |
| +45.82% | 765B | |
| +40.95% | 632B | |
| -6.16% | 354B | |
| +19.86% | 331B | |
| +9.32% | 299B | |
| +18.45% | 248B | |
| -0.78% | 219B | |
| +11.88% | 216B | |
| +5.90% | 164B |
- Stock Market
- Equities
- MDCX Stock
